Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Gerber

Showing results (81-90 of 103) with videos related to

Pageof 11
Sort By:
Molecular Cancer Therapeutics|August 30, 2008
Anti-CD30 diabody-drug conjugates with potent antitumor activityKristine M Kim, Charlotte F McDonagh, Lori Westendorf, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 26, 2014
Glioblastoma multiforme metastasis outside the CNS: three case reports and possible mechanisms of escapeJackson D Hamilton, Marion Rapp, Timo Schneiderhan, et al.
Translational Oncology|December 18, 2020
Vanucizumab mode of action: Serial biomarkers in plasma, tumor, and skin-wound-healing biopsiesFlorian Heil, Galina Babitzki, Alice Julien-Laferriere, et al.
The New England Journal of Medicine|March 14, 2008
VEGF inhibition and renal thrombotic microangiopathyVera Eremina, J Ashley Jefferson, Jolanta Kowalewska, et al.
Blood|January 17, 2009
Potent antitumor activity of the anti-CD19 auristatin antibody drug conjugate hBU12-vcMMAE against rituximab-sensitive and -resistant lymphomasHans-Peter Gerber, May Kung-Sutherland, Ivan Stone, et al.
Molecular Cancer Therapeutics|April 28, 2025
The anti-FRα antibody-drug conjugate luveltamab tazevibulin demonstrates efficacy in non-small cell lung cancer preclinical models and induces immunogenic cell deathRobert Yuan, Andrew McGeehan, Sihong Zhou, et al.
Cell|October 16, 2012
Soluble FLT1 binds lipid microdomains in podocytes to control cell morphology and glomerular barrier functionJing Jin, Karen Sison, Chengjin Li, et al.
Cancer Immunology, Immunotherapy : CII|October 26, 2017
A CD3-bispecific molecule targeting P-cadherin demonstrates T cell-mediated regression of established solid tumors in miceTimothy S Fisher, Andrea T Hooper, Justin Lucas, et al.
Molecular Cancer Therapeutics|December 11, 2012
Long-term tumor regression induced by an antibody-drug conjugate that targets 5T4, an oncofetal antigen expressed on tumor-initiating cellsPuja Sapra, Marc Damelin, John Dijoseph, et al.
The AAPS Journal|April 26, 2017
Site Selection: a Case Study in the Identification of Optimal Cysteine Engineered Antibody Drug ConjugatesL Nathan Tumey, Fengping Li, Brian Rago, et al.
Pageof 11

Showing results (81-90 of 103) with videos related to

Sort By:
Pageof 11
Molecular Cancer Therapeutics|August 30, 2008
Anti-CD30 diabody-drug conjugates with potent antitumor activityKristine M Kim, Charlotte F McDonagh, Lori Westendorf, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 26, 2014
Glioblastoma multiforme metastasis outside the CNS: three case reports and possible mechanisms of escapeJackson D Hamilton, Marion Rapp, Timo Schneiderhan, et al.
Translational Oncology|December 18, 2020
Vanucizumab mode of action: Serial biomarkers in plasma, tumor, and skin-wound-healing biopsiesFlorian Heil, Galina Babitzki, Alice Julien-Laferriere, et al.
The New England Journal of Medicine|March 14, 2008
VEGF inhibition and renal thrombotic microangiopathyVera Eremina, J Ashley Jefferson, Jolanta Kowalewska, et al.
Blood|January 17, 2009
Potent antitumor activity of the anti-CD19 auristatin antibody drug conjugate hBU12-vcMMAE against rituximab-sensitive and -resistant lymphomasHans-Peter Gerber, May Kung-Sutherland, Ivan Stone, et al.
Molecular Cancer Therapeutics|April 28, 2025
The anti-FRα antibody-drug conjugate luveltamab tazevibulin demonstrates efficacy in non-small cell lung cancer preclinical models and induces immunogenic cell deathRobert Yuan, Andrew McGeehan, Sihong Zhou, et al.
Cell|October 16, 2012
Soluble FLT1 binds lipid microdomains in podocytes to control cell morphology and glomerular barrier functionJing Jin, Karen Sison, Chengjin Li, et al.
Cancer Immunology, Immunotherapy : CII|October 26, 2017
A CD3-bispecific molecule targeting P-cadherin demonstrates T cell-mediated regression of established solid tumors in miceTimothy S Fisher, Andrea T Hooper, Justin Lucas, et al.
Molecular Cancer Therapeutics|December 11, 2012
Long-term tumor regression induced by an antibody-drug conjugate that targets 5T4, an oncofetal antigen expressed on tumor-initiating cellsPuja Sapra, Marc Damelin, John Dijoseph, et al.
The AAPS Journal|April 26, 2017
Site Selection: a Case Study in the Identification of Optimal Cysteine Engineered Antibody Drug ConjugatesL Nathan Tumey, Fengping Li, Brian Rago, et al.
Pageof 11